Form 4: BeOne Medicines Officer Sells Shares for Tax Withholding

BeOne Medicines' Principal Accounting Officer, Titus B. Ball, sold 122 American Depositary Shares to cover tax obligations related to a restricted share unit vesting.

Summary

• Titus B. Ball, Principal Accounting Officer of BeOne Medicines Ltd., reported a transaction on September 2, 2025.
• The transaction involved the sale of 122 American Depositary Shares (ADS) at a price of $326.76 per ADS.
• This sale was executed to satisfy mandatory tax withholding requirements associated with the vesting of a restricted share unit (RSU) award.
• Each American Depositary Share represents 13 Ordinary Shares.
• Following this transaction, Mr. Ball directly owns 72,397 Ordinary Shares and 0 American Depositary Shares.
• The underlying RSU award vests 1/4th on each anniversary of August 31, 2023, contingent on continued service.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled.

Sentiment

Score: 7

Explanation: The transaction is a non-discretionary sale for tax purposes, which is a neutral event. The underlying RSU vesting is positive for executive retention and aligns management incentives with shareholder interests.

Positives

• Vesting of restricted share units indicates continued compensation and retention of a key officer.
• The sale was non-discretionary, solely for mandatory tax withholding purposes, rather than a voluntary divestment.

Negatives

• A reduction in direct beneficial ownership of American Depositary Shares by a key officer, even if for tax purposes.

Future Outlook

Future vesting of restricted share units is scheduled to occur in 1/4th increments on each anniversary of August 31, 2023, contingent upon the reporting person's continued service.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: Minor reduction in direct beneficial ownership by a key officer, but the underlying RSU vesting aligns management incentives with shareholder interests.
• Employees: Demonstrates the company's compensation structure for key executives, potentially impacting morale and retention.

Next Steps

• Future vesting of remaining restricted share units on anniversaries of August 31, 2023, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an officer for tax withholding purposes following an RSU vesting. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment stance. The underlying RSU vesting is a positive for executive retention, but the sale itself is a neutral event. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a buy or sell decision based solely on this filing.

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Stock Sale, Restricted Share Units, Tax Withholding, Titus B. Ball, Principal Accounting Officer, American Depositary Shares